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a  b  s  t  r  a  c  t
Background:  Unsafe  injecting  practices  put  injecting  drug  users  (IDUs)  at repeat  exposure  to  infection
with  the  hepatitis  C  virus  (HCV).  It has not  yet  been  determined  if spontaneously  clearing  one’s  primary
infection  inﬂuences  the  risk  of  reinfection;  our  aim  was to  estimate  the  relative  risk  of  reinfection  in IDUs
who  have  cleared  the  virus.
Methods:  We  conducted  a retrospective  study  using  a large  database  of  HCV  test results  covering  Greater
Glasgow  Health  Board  during  1993–2007  to calculate  rates  of  infection  and  reinfection  in current/former
IDUs.  The  relative  risk  of (re)infection  in  previously  infected  compared  with  never-infected  IDUs  was
estimated  using  Poisson  regression,  adjusting  for  age  at study  entry,  sex,  and  calendar  period  of  test.
Results: Although  the  rate  of  reinfection  in  IDUs  who  were  HCV  antibody-positive,  RNA-negative  at  base-
line  was  lower  (7/100  person-years,  95%  CI: 5–9) than  the  rate  of  acute  infection  in IDUs  who  were
HCV  antibody-negative  at baseline  (10/100  person-years,  95%  CI: 9–12),  the risk  of  reinfection  was not
signiﬁcantly  different  than the risk  of  initial  infection  (adjusted  rate  ratio  =  0.78,  95%  CI: 0.57–1.08).
Conclusion:  We  found  only  weak  evidence  for a reduced  risk  of  HCV  reinfection  in IDUs  who  had  cleared
their  previous  infection.  Further  research  among  those  who  have  cleared  infection  through  antiviral
therapy  is  needed  to help  inform  decisions  regarding  treatment  of  IDUs.
© 2012 Elsevier B.V. All rights reserved.
Introduction
The Scottish Government’s recent initiative addressing the hep-
atitis C epidemic (Scottish Government Health Department, 2008) –
in which nationwide prevalence among injecting drug users (IDUs)
is estimated at 53% in 2008, with 1000–1500 IDUs newly acquiring
hepatitis C virus infection (HCV) each year (Scottish Government,
2011) – aimed to increase the number of infected individuals com-
mencing treatment from 500 per year in 2008/2009 to at least
2000 per year from 2011/2012. Data regarding reinfection rates are
needed to inform on efforts to prevent HCV among IDUs, as well as
the treatment of current IDUs. A clearer understanding of the risks
of reinfection and the possibility of protective partial immunity in
active IDUs is important when planning the provision of antiviral
therapy, particular among individuals with ongoing risk exposure.
Approximately 26% of persons with acute HCV infection are able
to spontaneously clear the virus (Micallef, Kaldor, & Dore, 2006) and
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the remainder become chronically infected, with the consequent
risk of HCV-related disease progression: liver ﬁbrosis, cirrhosis
and hepatocellular carcinoma. For IDUs, who  represent the largest
at-risk group in Australia, USA, UK and other Western European
countries (Alter et al., 1999; Dore, MacDonald, Law, & Kaldor, 2003;
Health Protection Agency, 2009; Trepo & Pradat, 1999), the majority
of transmission occurs through the sharing of contaminated inject-
ing equipment, and so there is much opportunity for reinfection
among those IDUs who  do not use clean needles/syringes on each
injecting occasion.
There is a lack of consistent evidence regarding the question of
whether previous HCV infection confers partial immunity upon re-
exposure, and so leads to a lower risk of re-infection compared with
the risk of new infection (Corson, Greenhalgh, Palmateer, Weir, &
Hutchinson, 2011; Currie et al., 2008; van de Laar et al., 2009); such
a lower risk of reinfection was  observed in three cohort studies
(Farci et al., 1992; Grebely et al., 2006; Mehta et al., 2002). How-
ever, two other studies indicated a higher infection rate among
previously-infected compared with never-infected IDUs (Aitken
et al., 2008; Micallef et al., 2007), although the incidence rate ratio
in the latter study was  not statistically signiﬁcant after adjustment
for behavioural covariates.
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Our goal was therefore to estimate the relative risk of
reinfection after viral clearance, by comparing rates of initial
infection (in those testing antibody[Ab]−/PCR−) and reinfection
(in those testing Ab+/PCR−, that is, who had cleared their pri-
mary infection) among IDUs identiﬁed within a large laboratory
database of HCV test results for Greater Glasgow Health Board
(GGHB). An estimated 40% (20,000/50,000) of Scotland’s HCV
infected population (Scottish Government Health Department,
2008) and 37% (8862/23,933) of mainland Scotland’s IDU popula-
tion (Hay, Gannon, Casey, & McKeganey, 2009) currently live within
GGHB.
Methods
Study population and data sources
Health Protection Scotland (HPS) maintains a database –
through sourcing records from the West of Scotland Specialist
Virology Centre – of all persons who have undergone an HCV
Ab and/or HCV PCR test in NHS Greater Glasgow Health Board.
HCV antibody reactivity in blood specimens was detected using
an enzyme linked immunosorbent assay (ELISA) and a supple-
mental RIBA-3 test (Ortho Diagnostics). The presence of HCV RNA
was ascertained using an in-house method following a positive
ELISA result. A second sample is immediately requested from
the clinician to conﬁrm RNA status in HCV Ab reactive indi-
viduals; therefore, initial test result was deﬁned as either an
Ab− test, or an initial Ab+ test followed by a PCR test within
1 month.
Individual records on the HCV test database held at HPS contain
the following non-named information: sex, date of birth, surname
soundex code, and forename initial, as well as data concerning risk
activities (classiﬁed into reported IDU and not-known). We  used a
strict deterministic approach (that is, required complete matches
on all available identiﬁers) to map  individual test records to dis-
tinct persons. Following this step, data for 97,250 individuals who
had been tested at least once for HCV between 1993 and 2007 were
available. Extra data on risk activities were obtained via determin-
istic record-linkage to the national HIV test database also held by
HPS (Goldberg, Davis, Allardice, McMenamin, & Codere, 1996). This
database contained records for 415,555 HIV tests conducted over
the period 1988–2007, among which 36,618 mention IDU as risk
activity. 26,807 (27.6%) of HCV-tested persons linked to the HIV
test database.
Two subcohorts were deﬁned: (i) those current/former IDUs
who had no evidence of past HCV infection, that is, initial test
result was Ab− and if also PCR tested at the same time, PCR− (the
Never-infected subcohort); and (ii) those IDUs with evidence of
past infection but no viraemia at initial test, that is, Ab+/PCR− (the
previously-infected subcohort).
We  checked that our previously-infected subcohort did not
include IDUs who  had received antiviral therapy, to guard against
treatment relapse being interpreted as reinfection. This was done
via deterministic record-linkage to the Scottish HCV Clinical
Database (a database containing clinical follow-up data on HCV
infected patients attending antiviral treatment clinics in Scotland),
matching on date of birth, sex, and initials. Only one IDU was iden-
tiﬁed, who achieved a sustained response and was PCR− at second
test.
The study population thus consisted of those individuals on
the HCV test database who had complete data on sex and date
of birth (and so excluding 17 persons), who had IDU indicated as
risk activity leading to infection, who were initially HCV tested
in the period 1993–2007, and had at least one subsequent HCV
PCR test (or Ab− if no subsequent PCR test) (Never-infected
subcohort; n = 829), or at least one subsequent PCR test (previously-
infected subcohort; n = 347). Based on linkage to the HIV test
database, 10/1176 participants (<0.1%) were determined to be HIV-
infected.
Data analysis
We  computed frequencies and rates of the incidence of
(re-)infection in the two subcohorts deﬁned above. First, in those
IDUs who  initially tested Ab+/PCR− (previously-infected subco-
hort), follow-up time was deﬁned as time from initial test to the
midpoint of the interval between the date of the last negative PCR
test and the date of the ﬁrst positive PCR test. If no positive PCR test
was ever recorded for an individual, follow-up time was censored at
date of the last negative PCR test. ‘Reinfection’ was deﬁned as such
if a member of the previously-infected cohort tested PCR+ at least
once during follow-up. Second, in those IDUs who tested Ab− at
initial test (the Never-infected subcohort), follow-up time was sim-
ilarly deﬁned as time from date of initial test to the midpoint of the
interval between the date of the last negative test and date of ﬁrst
positive PCR test. If no positive PCR test was ever recorded, follow-
up was censored at date of the last negative PCR test. Because a PCR
test is normally only conducted if the result of the Ab test is positive,
we considered an Ab− result to be a proxy for PCR−. ‘New infec-
tion’ was deﬁned as such if a member of the Never-infected cohort
tested PCR+ at least once during follow-up. Conﬁdence intervals
for rates were computed using the exact Poisson method. Rela-
tive risks were estimated using Poisson regression as rate ratios
adjusted for sex, age, and calendar period of test. All statistical anal-
yses were carried out using R version 2.7.2 (R Development Core
Team, 2008).
Sensitivity analyses were conducted to assess the inﬂuence of
constraining the maximum inter-test interval on the adjusted rate
ratio for reinfection of previously-infected compared with infec-
tion of Never-infected subcohorts. In this analysis, we successively
re-deﬁned the study population to include only those individuals
with a maximum time from initial test to ﬁrst subsequent PCR test
of 1 through 5 years (in steps of 0.5 years), and re-ran the regres-
sion analysis to compare the adjusted rate ratios to that obtained
with no constraint on this interval (the default analysis). An addi-
tional sensitivity analysis addressed the potential inﬂuence from
improvements in PCR test sensitivity over the study period; in this
analysis data were restricted to initial testing conducted within the
period 2002–2007 only.
Results
Demographic characteristics of the two  subcohorts at date
of initial test differed in terms of mean age (Table 1); the
IDUs in the Never-infected subcohort were signiﬁcantly younger
than in the previously-infected subcohort (M = 28.4 years; SD = 8.2
and M = 31.7 years; SD = 6.3, respectively; p < 0.0001). The median
time to ﬁrst subsequent test was much longer for the Never-
infected compared with the previously-infected subcohort (1.6 and
0.4 years, respectively; p < 0.0001) (Table 2).
Median follow-up time (in which time of (re)infection was
imputed), considering date of initial test to be time-zero, was
1.4 years (IQR: 0.5–3.0) and 1.2 years (IQR: 0.2–3.2) for the Never-
infected and previously-infected subcohorts, respectively. Of the
Never-infected subcohort, 173/829 (21%) had a subsequent posi-
tive PCR test; the infection rate was  10 per 100 person-years (95%
CI: 9–12). Of the previously-infected subcohort, 53/347 (15%) sub-
sequently tested PCR positive, with a reinfection rate of 7 per 100
person-years (95% CI: 5–9). The overall incidence (aggregating new
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Table 1
Characteristics of the study population, consisting of IDUs resident in Greater Glasgow Health Board who were tested for HCV infection in the period 1993–2007 and who
either  initially tested Ab-negative (Never-infected subcohort) or initially tested Ab-positive/PCR-negative (Previously-infected subcohort).
Initial HCV test status
Ab− Ab+/PCR− All
Number of IDUs 829 347 1176
Males  (%) 539 (65.0) 216 (62.2) 755 (64.2)
Mean age at initial test, in years (SD) 28.4 (8.2) 31.7 (6.3) 29.4 (7.8)
Initial  test <2000 (%) 284 (34.3) 85 (24.5) 369 (31.4)
Initial test 2000–2003 393 (47.4) 171 (49.3) 564 (48.0)
Initial test 2004–2007 152 (18.3) 91 (26.2) 243 (20.6)
Mean number of subsequent PCR tests 1.3 1.8 1.4
Median years from initial test to ﬁrst subsequent PCR test (IQR) 1.6 (0.5–3.4) 0.4 (0.1–1.7) 1.2 (0.3–3.1)
Note: IQR = interquartile range; IDU = injecting drug user. IDU status was deﬁned using risk activities ﬁelds in the HCV test and linked HIV  test databases.
infections and reinfections) was 9 per 100 person-years (95% CI:
8–11).
There was weak evidence for a reduced risk of reinfection
for IDUs testing Ab+/PCR− at initial test compared with those
testing Ab− after adjustment for sex, age, and calendar period
(adjusted rate ratio [RR] = 0.78, 95% CI: 0.57–1.08) (Table 3). There
were statistically signiﬁcant effects of age at initial test (compared
with <25 years, 25–34 years: RR = 0.64, 95% CI: 0.48–0.85; and 35+
years: RR = 0.56, 95% CI: 0.35–0.90), and of calendar period of test
(compared with 2000–2003, <2000: RR = 0.55, 95% CI: 0.37–0.82;
<2004–2007: RR = 0.60, 95% CI: 0.43–0.83).
The sensitivity analysis indicated that the adjusted rate ratio
for initial test status was  not underestimated by including the full
range of inter-test intervals; deﬁning the eligible study population
with respect to a range (1–5 years) of maximum inter-test intervals
resulted in adjusted rate ratios generally lower to that obtained
with no inter-test interval restriction (RR central estimate ranged
from 0.54 to 0.74). The second sensitivity analysis – addressing any
effect from improvements in PCR test sensitivity over the study
period – indicated a comparable estimated relative risk for initial
test status (RR = 0.82, 95% CI: 0.55–1.22) was obtained.
Discussion
We found only weak evidence for a reduced risk of HCV
(re)infection in IDUs who had cleared their previous infection com-
pared with IDUs who were Ab− at initial test. Adjustment for age
(a proxy variable for risky injecting practices and injecting career
length (Golub et al., 2007; Lum, Sears, & Guydish, 2005)) and adjust-
ment for sex and calendar period changed the unadjusted rate ratio
for initial test status only slightly.
Our principal ﬁnding, though not statistically signiﬁcant, is
consistent in direction with results of two other cohort studies
that found IDUs who had cleared infection had a signiﬁcantly
lower risk of (re)infection than never-infected IDUs (Grebely
et al., 2006; Mehta et al., 2002). Mehta et al. reported a lower
incidence of acute infection (6.0/100 person-years; n = 98) in
previously-infected compared with never-infected IDUs (10.5/100
person-years; n = 164) (Mehta et al., 2002). The other community-
based cohort study, by Grebely et al. consisted of 152 individuals
(48% of whom were self-reported IDUs) who had cleared HCV
and 926 individuals (26% IDUs) who  had never been infected; the
observed incidence rates of reinfection and new infection (deﬁned
as Ab− becoming Ab+) were 1.8/100 and 8.1/100 person-years,
respectively (Grebely et al., 2006). Our ﬁndings are inconsis-
tent with more recent studies involving smaller cohorts of IDUs
reporting a higher risk for the previously-infected group: one
study reported a statistically signiﬁcant adjusted rate ratio of 2.5
(Aitken et al., 2008), and the second a nonsigniﬁcant 1.1 (Micallef
et al., 2007). Possible reasons for discrepant ﬁndings across stud-
ies include differences in the selection and characteristics of the
two subgroups at study entry, changes in risk-taking behaviour
following diagnosis with HCV infection, differences in the inter-
val between initial and subsequent tests, and whether transient or
persistent HCV infection was being measured (Currie et al., 2008).
The estimated overall HCV RNA positivity rate for this Glas-
gow IDU population was  9/100 person-years for the period
1993–2007, lower than the seroconversion rate (28.2/100 person-
years) obtained in a study involving unlinked anonymous testing
of sera from Glasgow IDUs who underwent voluntary named HIV
testing in the period 1993–1998 (Roy et al., 2001), but compara-
ble to the estimate of 12/100 person-years from a study of 1115
HCV Ab− IDUs attending needle-exchange services in 2008–2009
(University of the West of Scotland, Health Protection Scotland and
West of Scotland Specialist Virology Centre, 2010). We  also calcu-
lated a comparable incidence measure (that is, the rate of testing
Table 2
Rates of infection or reinfection in IDUs who  have never been infected and IDUs who  have been previously-infected with HCV, respectively.
Never-infected (n = 829) Previously-infected (n = 347) Total
PCR+ (%) P-yrs Rate (95% CI) PCR+ (%) P-yrs Rate (95% CI) Rate (95% CI)
(All) 173 (20.9) 1674 10.3 (8.9–12.0) 53 (15.3) 766 6.9 (5.2–9.0) 9.3 (8.1–10.6)
Sex
Male  105 (19.5) 1035 10.1 (8.3–12.3) 31 (14.4) 444 7.0 (4.7–9.9) 9.2 (7.7–10.8)
Female 68 (23.4) 640 10.6 (8.3–13.5) 22 (16.8) 323 6.8 (4.3–10.3) 9.4 (7.5–11.5)
Age  at initial test (years)
<25 93 (29.6) 680 13.7 (11.0–16.7) 10 (18.9) 110 9.1 (4.4–16.8) 13.0 (10.6–15.8)
25–34  72 (18.6) 798 9.0 (7.1–13.4) 28 (14.1) 499 5.6 (3.7–8.1) 7.7 (6.3–9.4)
35+  8 (6.3) 196 4.1 (1.8–8.0) 15 (15.6) 157 9.5 (5.3–15.7) 6.5 (4.1–9.8)
Calendar year period (time-dependent)
<2000 20(7.0) 305 6.6 (4.0–10.1) 8 (8.9) 116 6.9 (3.0–13.6) 6.7 (4.4–9.6)
2000–3 122(21.0) 875 13.9 (11.6–16.7) 26 (10.7) 376 6.9 (4.5–10.1) 11.8 (10.0–13.9)
2004–7 31(8.6) 494 6.3 (4.3–8.9) 19 (9.2) 275 6.9 (4.2–10.8) 6.5 (4.8–8.6)
Note: PCR+ = number subsequently testing HCV RNA positive, with percentage PCR+ in each category; P-yrs = person-years of follow-up, starting from date of initial test; rate
is  per 100 person-years; CI = conﬁdence intervals.
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Table 3
Results of Poisson regression analyses on the rate of HCV infection in a study population consisting of IDUs who were tested for HCV in Greater Glasgow Health Board during
1993–2007 (n = 1176). The rate ratio (RR) for initial test status (Never-infected = Ab−; Previously-infected = Ab+/PCR−) is adjusted for sex, age and calendar year period
(time-dependent).
Factor Level N PCR + Unadj. RR 95% CI Adj. RR 95% CI
Initial test Never-infected 829 173 Ref. Ref.
Status Previously-infected 347 53 0.67 0.49–0.91 0.78 0.57–1.08
Sex  Female 421 90 Ref. Ref.
Male  755 136 0.98 0.75–1.28 1.05 0.80–1.37
Age  at initial test <25 367 103 Ref. Ref.
25–34  586 100 0.59 0.45–0.78 0.64 0.48–0.85
35+ 223 23 0.50 0.32–0.78 0.56 0.35–0.90
Calendar year period <2000 369 28 0.56 0.38–0.84 0.55 0.37–0.82
2000–2003 813 148 Ref. Ref.
2004–2007 554 50 0.55 0.40–0.76 0.60 0.43–0.83
Note: N = number of IDUs contributing to each category; PCR+ = number of IDUs subsequently testing HCV RNA positive; CI = conﬁdence interval.
Ab and/or RNA positive) for the Never-infected group in our study,
and arrived at 11/100 person-years.
Incidence increased from 7/100 person-years in 1993–1999 to
12/100 person-years in 2000–2003 and then decreased to 7/100
person-years in the most recent calendar period (2004–2007); the
decrease between 2000–2003 and 2004–2007 may reﬂect trends
in the rate of transmission of the virus (Hutchinson, McIntyre, &
Molyneaux, 2002), or a risk-behaviour selection effect, whereby of
all IDUs initially tested during 2000–2003, those with the riski-
est injection practices tended to get (re)infected relatively quickly,
and those with the least risky injection practices tended to remain
(re)infection-free. The decrease observed in the latter period is
consistent with a downward trend in the proportion of IDUs report-
ing the sharing of injecting equipment (Health Protection Agency,
2011). In addition, the second test for IDUs initially tested in the lat-
ter part of the study period may  not yet have occurred by the end of
2007, so these IDUs would have been excluded when determining
the study population.
Our database study had several limitations. First, because IDUs
were referred for subsequent HCV testing, estimated incidence
rates may  not be representative of those of the IDU population as a
whole, because referral may  have been prompted by report of risk-
taking behaviour. However, because members of both subcohorts
were tested subsequent to index test, incidence rate ratios should
be unaffected by referral bias.
We reported as much demographic data as we  had available
to compare the baseline characteristics of the Never-infected and
previously-infected subcohorts. Because the latter group was older
at study entry (by an average of 3.4 years), these individuals may
engage in fewer risk-taking behaviours (for example, sharing of
injecting equipment), especially after initially being diagnosed HCV
Ab+. Reasons for HCV test referral may  differ with age, with older
IDUs being referred because of a suspected higher risk of HCV infec-
tion (perhaps due to a longer reported injecting career). Further,
unmeasured baseline characteristics may  differ between subco-
horts and account for differences in HCV (re)infection incidence.
We assumed individuals to have been at risk of acquiring HCV
infection through continued injecting drug use during follow-up,
but the HCV test database lacks information on ongoing injecting
practice. However, age serves as a proxy variable for risk-taking
behaviours – albeit far from perfect – with younger IDUs tending to
engage in riskier injecting practices (Golub et al., 2007). Adjustment
for age in the regression analysis should have provided some degree
of control for age-related risk behaviour in the estimation of relative
risk.
In an ideal prospective study addressing the current research
question, a cohort of IDUs would be followed up at regular intervals
from their injection debut, and a time-dependent status variable
would be used to distinguish follow-up time (and therefore risk of
(re)-infection) before and after initial infection; thus; individuals
who clear the virus would contribute both Unexposed (pre-initial
infection) and Exposed (post-initial infection) follow-up time to
the analysis. However, given the necessarily retrospective design
of our database-linkage study, we had to deﬁne entry to study as
the initial test date and so could not address potential bias due to
any unmeasured difference in Unexposed follow-up time between
Never-infected and previously-infected subcohorts.
The longer interval from date of study entry to date of ﬁrst
Ab/PCR test for the Never-infected subcohort means that episodes
of transient viraemia were more likely to be missed in this sub-
cohort than in the previously-infected subcohort. The presence
of such bias means the rate for initially Ab− IDUs would tend to
be underestimated, leading to a higher rate ratio than in reality.
Related to this point, if individuals who  clear HCV spontaneously
are more likely to clear it again if reinfected (Osburn et al., 2010),
there would be a greater chance of missing short-lived periods
of viraemia in the previously-infected compared with the Never-
infected subcohort. However, the sensitivity analysis indicated only
small changes in relative risk if the maximum inter-test inter-
val was reduced substantially. Also because of the long inter-test
interval (and with no subsequent test available), we could not dis-
tinguish whether having been previously-infected had an effect on
reinfection risk or on viral persistence (Mehta et al., 2002).
It should be noted that the Never-infected group may  include
IDUs who have cleared the virus and subsequently their antibody.
However, although there is no laboratory marker to detect this
group, an immune recognition study of 26 young seronegative and
aviremic active IDUs found that 46% had HCV-speciﬁc, IFN- T-cell
responses, indicating previous exposure to HCV (Zeremski et al.,
2009).
Finally, reinfection rates with a different genotype may  differ
from rates of reinfection with same genotype. Due to insufﬁcient
data on genotype, we  were unable to address this important issue.
Genetic factors such as presence of an IL28B polymorphism have
been shown to be associated with natural clearance of HCV (Thomas
et al., 2009); we  could not control for such factors.
One suggestion for the mechanism by which partial protec-
tive immunity is gained after clearing initial HCV infection centres
on the deployment of adaptive immunity. In a prospective study
of 22 active IDUs who had spontaneously cleared their initial
HCV infection, 11 (50%) became reinfected, but of these indi-
viduals, 83% subsequently cleared their infection (Rahman et al.,
2004). Viraemia (maximum level of HCV RNA concentration and
duration) during reinfection episodes was  signiﬁcantly decreased
compared with measurements made after initial infection in the
same individuals, and a higher frequency of CD8+ T-cell responses
were detected in reinfected persons, indicating that cell-mediated
immune responses assist in the protective immunity resulting
after clearance of initial infection. A similar pattern of reinfec-
tion and reclearance was  reported in a study of 135 acutely
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infected young IDUs (Page et al., 2009). Although the immune
functions underlying the responsiveness of chronic infection to
combination (pegylated interferon + ribavirin) antiviral therapy are
incompletely understood (Bowen & Walker, 2005; Cramp et al.,
2000), weaker HCV-speciﬁc adaptive immune responses have been
observed in treatment responders compared with those who spon-
taneously resolved infection (Rahman et al., 2004).
Unfortunately, because our study population consists of those
IDUs referred for HCV testing, being tested may  play a role in terms
of inducing behavioural changes, meaning that one can not distin-
guish the role of the test from the role of immune mechanisms in
the estimated risk of reinfection reported here.
In conclusion, our ﬁndings are relevant for the goal of increasing
the annual numbers of recipients of antiviral therapy proposed in
the Hepatitis Action Plan for Scotland (Scottish Government Health
Department, 2008). Although ongoing injecting drug use has been
in practice a barrier for commencing an individual on treatment, if
a reduced risk of reinfection after spontaneous viral clearance can
be observed – and if also seen in those who have cleared infec-
tion through antiviral therapy (Backmund, Meyer, & Edlin, 2004;
Dalgard, 2005; Grebely et al., 2010) – this suggests that treatment
of both former and current IDUs may  be viable. The likelihood of
reinfection should be considered when conducting an assessment
of the beneﬁts and drawbacks of antiviral therapy of this population
for HCV infection.
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